Pneumagen’s Intranasal Flu Antiviral Demonstrates Promise in Phase 2 Human Challenge Study
October 3, 2023 : Pneumagen, a clinical-stage biotechnology company, has announced positive results from a phase 2 human challenge study of its intranasal flu antiviral, Neumifil. The study, conducted at a single center in London, UK, enrolled 104 healthy adults who received two doses of Neumifil before being intentionally exposed to the influenza virus.
Genetic Variant Linked to Increased Inflammation Risk Carried by Millions
October 3, 2023 :Researchers have identified a gene that increases the risk of inflammation, leading to various chronic diseases, including heart disease, stroke, and cancer. The gene, called MLKL, is carried by millions of people around the world.
